BUNGOWANNAH VIRUS
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission; Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory; Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Bungowannah virus is a genetically distinct pestivirus (species Pestivirus australiaense) that was identified as the cause of "porcine myocarditis syndrome" (PMC) during a severe disease outbreak in June 2003 on two related pig farms in southern New South Wales, Australia. The virus caused devastating reproductive losses characterized by increased stillbirths, preweaning mortality (reaching 50% at peak), mummified fetuses (13%), and sudden death in 2-3 week old piglets due to myocarditis. An estimated 50,000 pigs were lost from production over a 15-month period in a combined herd of approximately 30,000 sows. Critically, Bungowannah virus disease results almost entirely from in utero infection—postnatal infection causes minimal to no clinical effects, with infected sows showing no clinical signs despite transmitting virus to their fetuses. This makes the virus particularly insidious: by the time reproductive losses are recognized at farrowing, infection has already spread widely through the breeding herd. The virus was eradicated from the smaller affected farm (2007-2009), but initial eradication attempts at the larger multi-unit site failed due to suspected aerosol recontamination during decontamination procedures. Successful eradication was finally achieved in 2022 using partial depopulation combined with an autogenous live vaccine for replacement breeding females. The origin of Bungowannah virus remains unknown, and the natural host has not been identified. Despite its distant genetic relationship to CSFV, Bungowannah virus is not detected by diagnostic assays previously thought to react with all pestiviruses, raising concerns about potential undetected circulation elsewhere.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter states that pestiviruses as a group have "no evidence of human infection" and "are not of any significance for public health or food safety." Bungowannah virus, as a pestivirus, shares this characteristic. Despite extensive handling of infected pigs and tissues during the outbreak investigation and subsequent research, no human infections have been documented. The virus poses no known foodborne risk.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
No human infections with Bungowannah virus have been documented despite extensive occupational exposure during outbreak investigation, eradication efforts, and experimental studies. Veterinarians, farm workers, and laboratory personnel handling infected animals and tissues have not developed illness attributable to the virus. Like other pestiviruses, Bungowannah virus appears to have no zoonotic potential.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission
Bungowannah virus transmission occurs primarily through oronasal exposure, with persistently infected pigs shedding high quantities of virus in oropharyngeal secretions, urine, and feces that readily infect naive pigs. Transplacental transmission is highly efficient—fetal infection occurred in 87% of litters from experimentally infected sows. However, transmission from transiently infected animals appears relatively poor, and the virus does not survive well in the environment (sentinel pigs placed in uncleaned areas 3 days after infected pigs were removed did not become infected). The most significant spread occurs following farrowing of affected litters, when placental fluids and fetal materials heavily contaminate the environment. The virus remained endemic on the larger affected farm primarily through continuous transient infections of large numbers of susceptible animals associated with weekly animal movements in a continuous-flow operation. The failed eradication attempt in 2009-2010 was attributed to aerosol transmission during decontamination of an infected module 0.5-1.5 km away, demonstrating that under certain conditions the virus can spread beyond direct contact. Bungowannah virus RNA has been detected in semen of approximately 20% of boars despite high serum neutralizing antibody titers, though the infectivity of this semen via artificial insemination has not been determined. Standard biosecurity with emphasis on preventing introduction of infected animals and controlling movement of potentially contaminated materials can be effective.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory
Bungowannah virus presents significant diagnostic challenges. Clinical signs are not pathognomonic—the presentation (stillbirths, preweaning mortality, mummified fetuses, myocarditis in neonates) overlaps with multiple other conditions including in utero infection with CSFV, BVDV, BDV, and "late onset" CSF. Critically, affected sows show no clinical signs despite active infection, and postnatal infection in pigs of any age causes minimal to no disease. This means the virus can circulate undetected in a population until reproductive losses become apparent at farrowing—weeks after initial infection. Even more concerning, Bungowannah virus is genetically so distinct from other pestiviruses that it is not detected by diagnostic assays previously thought to react with all members of the genus Pestivirus. This raises the possibility of undetected circulation in other regions. Laboratory diagnosis requires: real-time RT-PCR (rapid, sensitive, preferred method) using Bungowannah-specific primers; virus isolation in porcine kidney cells (virus is non-cytopathic, requiring immunoperoxidase staining for verification); and serology by peroxidase-linked immunoassay (PLA) or virus neutralization. Specific antibodies can be detected in serum and body cavity fluids of stillborn piglets. Diagnostic expertise and reagents are limited to specialized laboratories, primarily in Australia.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
The original Bungowannah virus outbreak caused devastating losses. In a combined herd of approximately 30,000 sows, an estimated 50,000 pigs were lost from production over a 15-month period. At peak outbreak: preweaning mortality reached 50%; up to 40% of fetuses were stillborn; 13% were mummified. The sudden death of healthy 2-3 week old piglets due to myocarditis triggered the initial investigation, but losses evolved to predominantly reproductive failure as the outbreak progressed. Individual affected litters showed dramatically reduced viability—piglets born alive from affected litters had greatly reduced survival. When sows were experimentally infected at 35 days of gestation (the most damaging timing), approximately 40% of fetuses were stillborn or mummified, and 70% of piglets born alive died before weaning. The few survivors were often persistently infected and developed severe stunting with high morbidity and mortality—a presentation similar to "late onset CSF." Losses extend beyond direct mortality: non-productive sow days from failed pregnancies, reduced litter sizes, culling of affected breeding stock, and the substantial costs of eradication efforts including depopulation, cleaning, disinfection, and restocking. The prolonged nature of endemic infection on the larger affected farm (2003-2022) imposed ongoing costs until successful eradication.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms
Although Bungowannah virus is not currently WOAH-listed, detection in a new country would trigger significant regulatory and trade consequences. The virus is a novel pestivirus with unknown origin and reservoir—factors that would prompt precautionary responses from trading partners. Its clinical similarity to CSFV (particularly the "carrier sow syndrome" and reproductive losses) would require extensive investigation to rule out CSFV and other regulated pathogens. Australia contained the virus to two related farms, preventing broader market impacts, but detection in a major pork-exporting country would likely cause: immediate notification and investigation requirements; precautionary trade restrictions pending characterization; extensive surveillance to determine distribution; and prolonged negotiations over risk assessment and market access conditions. The diagnostic challenge—Bungowannah virus is not detected by pan-pestivirus assays—would complicate efforts to demonstrate freedom. The combination of severe reproductive impact, unknown origin, diagnostic difficulty, and novelty would create substantial market uncertainty even if the virus proved to be geographically limited.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Bungowannah virus is a viral pathogen (positive-sense single-stranded RNA pestivirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for Bungowannah virus. Disease management focuses on prevention (biosecurity, vaccination of breeding females before mating) and eradication (depopulation, cleaning, disinfection). Antimicrobials are not used in outbreak response. Secondary bacterial infections are not a significant feature of the disease—the primary pathology is viral myocarditis and reproductive failure. The successful 2022 eradication used partial depopulation and autogenous vaccination, not antimicrobial therapy.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments exist for Bungowannah virus infection. The disease results from in utero fetal infection—by the time reproductive losses are recognized at farrowing, damage has already occurred. Myocarditis in neonatal piglets is not treatable. Sows clear postnatal infection through their own immune response without requiring treatment (and without showing clinical signs). Persistently infected piglets cannot clear the virus and eventually die or develop severe stunting. Management is entirely preventive: maximizing exposure of breeding animals prior to mating to establish immunity, or vaccination of replacement females.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No commercial vaccine exists for Bungowannah virus. However, an autogenous live vaccine was developed and used successfully in the 2022 eradication effort—all replacement breeding females were vaccinated prior to breeding as part of the partial depopulation strategy. Natural immunity following postnatal infection is robust: antibody is detected from 12 days post-inoculation in weaner pigs, with antibody production associated with viral clearance and cessation of shedding. High neutralizing antibody titers develop and are maintained for at least 2-3 months post-farrowing in naturally infected sows. Maternally derived antibody wanes by approximately 2 months of age in piglets. The successful use of autogenous vaccine demonstrates that vaccination is feasible, but no licensed commercial product is available. Given the virus has only been detected in Australia and was recently eradicated, commercial vaccine development is unlikely unless the virus is detected elsewhere.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
Bungowannah virus has never been detected in the United States and was successfully eradicated from both affected Australian farms—the smaller farm in 2007-2009 and the larger multi-unit complex in 2022. Eradication is feasible because: (1) The virus does not survive well in the environment—susceptible sentinel pigs placed in contaminated areas 3 days after infected pigs were removed did not become infected; (2) Transmission from transiently infected animals is poor; (3) Standard cleaning and disinfection (detergent, Virkon, sodium hypochlorite) appears effective; (4) Postnatal infection produces robust immunity that clears the virus; (5) No wildlife reservoir has been identified. The Australian experience demonstrated two successful approaches: (a) Complete depopulation, cleaning, disinfection, and restocking with unexposed animals; (b) Partial depopulation combined with vaccination of all replacement breeding females before mating. The failed 2009-2010 attempt at the larger farm (attributed to aerosol recontamination during decontamination) highlights the importance of careful biosecurity during eradication procedures. If Bungowannah virus or a similar novel pestivirus were detected in the US, eradication would be achievable using these established protocols, with success dependent on early detection before widespread dissemination.